Defunct Company
Total Trials
3
As Lead Sponsor
0
As Collaborator
Total Enrollment
75
NCT02562378
T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer
Phase: Phase 1
Role: Collaborator
Start: Oct 31, 2015
Completion: Dec 31, 2018
NCT02506816
Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
Phase: N/A
Start: Feb 29, 2016
Completion: Mar 31, 2019
NCT03977714
Non-invasive Solution for Periodontal and Peri-implant Diseases (INPERIO)
Start: Aug 2, 2019
Completion: Jul 4, 2022